Laura Michaelis, MD

Chief, Professor

view physician profile

Locations

Froedtert Hospital
Clinical Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Medical Oncology
Hematology

Languages

English

Clinical Cancer Center - Froedtert Hospital

(414) 805-0505

Moorland Reserve Health Center

(262) 798-7200

Education

MD - Doctor of Medicine

Biography

Laura Michaelis, MD, is a professor of medicine (hematology and oncology) at the Medical College of Wisconsin, specializing in Acute and Chronic Leukemias, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Bone Marrow Failure Syndromes, and Myeloid Disorders. She graduated from Harvard Medical School in 2000, then completed her internal medicine residency at Brigham and Women’s Hospital in Boston, MA. She received the Arnold Dunne Award for compassionate care in the practice of medicine during her residency. In 2003, Dr. Michaelis relocated to Chicago, IL, where she completed a hematology/oncology fellowship at the University of Chicago. Dr. Michaelis served as an assistant professor of medicine and program director of the Hematology and Oncology Fellowship Program at Loyola University Medical Center before joining MCW.

Research Interests

Dr. Michaelis's clinical research focuses on Leukemia, Myelodysplastic Syndromes and Myeloproliferative Neoplasms. She serves as director of inpatient services for the division of Hematology/Oncology and was appointed to be one of the Associate Vice Chairs of the Department of Medicine. Dr. Michaelis is board certified in Hematology and Medical Oncology.

How I diagnose and treat thrombocytopenia in geriatric patients.

(Foy P, Friedman KD, Michaelis LC.) Blood. 2024 Jan 18;143(3):214-223 PMID: 37956435 11/13/2023
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

(Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM.) Lancet Haematol. 2023 Sep;10(9):e767-e776 PMID: 37572683 08/13/2023
Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy.

(Taylor S, Murthy GSG, Runaas L, Michaelis LC, Carlson K, Atallah EL, Abedin SM.) Leuk Res. 2023 Sep;132:107348 PMID: 37423073 SCOPUS ID: 2-s2.0-85164434355 07/10/2023
PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.

(Moyo TK, Kishtagari A, Villaume MT, McMahon B, Mohan SR, Stopczynski T, Chen SC, Fan R, Huo Y, Moon H, Tang Y, Bejan CA, Childress M, Anderson I, Rawling K, Simons RM, Moncrief A, Caza R, Dugger L, Collins A, Dudley CV, Ferrell PB, Byrne M, Strickland SA, Ayers GD, Landman BA, Mason EF, Mesa RA, Palmer JM, Michaelis LC, Savona MR.) Clin Cancer Res. 2023 Jul 05;29(13):2375-2384 PMID: 37036505 04/11/2023
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.

(Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, Schroeder MA, Uy GL, Law LY, Cheema F, Sweet KL, Asch AS, Liu JJ, Moseley AB, Maher T, Kingsbury LL, Fang M, Radich J, Little RF, Erba HP.) Leuk Lymphoma. 2023 Feb;64(2):473-477 PMID: 36517990 PMCID: PMC10652187 12/16/2022
Identifying Credible Sources of Health Information in Social Media: Phase 2-Considerations for Non-Accredited Nonprofit Organizations, For-Profit Entities, and Individual Sources.

(Burstin H, Curry S, Ranney ML, Arora V, Wachler BB, Chou WS, Correa R, Cryer D, Dizon D, Flores EJ, Harmon G, Jain A, Johnson K, Laine C, Leininger L, McMahon G, Michaelis L, Minhas R, Mularski R, Oldham J, Padman R, Pinnock C, Rivera J, Southwell B, Villarruel A, Wallace K.) NAM Perspect. 2023;2023 PMID: 37916063 PMCID: PMC10617996 11/02/2023
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.

(Othus M, Thomas I, Wang X, Ariti C, Mehta P, Sydenham M, Hills RK, Burnett AK, Nand S, Assouline S, Michaelis LC, Erba HP, Russell N, Kerr KF, Walter RB, Dennis M.) Leuk Lymphoma. 2023 Jan;64(1):250-252 PMID: 36226777 PMCID: PMC10662133 10/14/2022
Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia.

(Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, Atallah E.) Leuk Res. 2022 Dec;123:106984 PMID: 36401944 SCOPUS ID: 2-s2.0-85141943453 11/20/2022
Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies.

(Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS.) Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e495-e497 PMID: 35148976 PMCID: PMC8767926 SCOPUS ID: 2-s2.0-85132179962 02/13/2022
A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm.

(Dong A, Pan X, Lin CW, Huang YW, Krause H, Pan P, Baim A, Thomas MJ, Chen X, Yu J, Michaelis L, Liu P, Wang LS, Atallah E.) J Cancer Prev. 2022 Jun 30;27(2):129-138 PMID: 35864858 PMCID: PMC9271408 07/23/2022
Progressive nodular histiocytosis with dramatic response to cobimetinib.

(Berce PC, Cardwell L, Essenmacher AN, Michaelis LC, Wanat KA.) JAAD Case Rep. 2022 Apr;22:110-113 PMID: 35372654 PMCID: PMC8971330 04/05/2022
Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome.

(Corrao K, Rezwan S, Atallah E, Michaelis LC, Runaas L, Harrington AM, Abedin S.) Leuk Res Rep. 2022;17:100329 PMID: 35651540 PMCID: PMC9150024 SCOPUS ID: 2-s2.0-85131561638 06/03/2022